U.S. President Donald Trump has nominated Dr. Heidi Overton, a top White House aide, to lead the Food and Drug Administration (FDA). The announcement was made Wednesday, positioning Overton to take over the agency following the departure of former FDA head Dr. Marty Makary, who resigned in May.
Overton currently serves as a medical doctor and deputy director of the White House Domestic Policy Council, working on second-term health initiatives. Her professional background includes attending medical school at the University of New Mexico and earning a doctoral degree in clinical investigation from Johns Hopkins University. Before joining the administration, she worked as the chief policy officer at the America First Policy Institute.
If confirmed by the Senate, Overton will face a complex regulatory landscape. She must balance Trump's stated priorities of faster drug approvals, innovation, lower drug prices, and the goals of Health Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" movement, alongside the anti-regulatory interests of traditional Republicans.
Her nomination comes at a time of significant transition and pressure within the agency. Makary's tenure concluded leaving several unfinished projects, including work on ultraprocessed foods, antidepressants, and COVID-19 shots. In addition, pharmaceutical and biotech companies have raised concerns over recent rejections or reversals of treatments for rare diseases, while food and tobacco sectors await clarity on regulations regarding flavored e-cigarettes and nicotine pouches.
Overton's public positions have already drawn both support and criticism. She has appeared alongside Trump to announce major projects, including "most favored nation" drug pricing deals and a recent vaccine order aiming to split the combined measles, mumps, and rubella (MMR) vaccine into three separate immunizations. She has also been critical of abortion pills and could potentially be positioned to review FDA rules regarding their accessibility.
The confirmation process will require approval from a narrowly Republican-led Senate and questioning from the Senate Health, Education, Labor and Pensions Committee. Committee chair Sen. Bill Cassidy expressed strong concerns regarding her lack of managerial experience and her involvement in the recent MMR vaccine order, calling it nearly disqualifying. Democratic senators have also strongly opposed the nomination.
"Leadership changes at major regulatory bodies like the FDA carry substantial weight for businesses operating in the healthcare, pharmaceutical, and biotechnology sectors. When regulatory priorities shift between fast-tracking innovation, lowering drug prices, and managing public health mandates, companies must remain agile to navigate evolving compliance standards. For investors and entrepreneurs in life sciences, regulatory predictability is critical for long-term planning, capital allocation, and bringing essential treatments to market." — Dr. Shishir Gupta, Founder & CEO, StartupLanes
